Jan Skvarka Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

ZNTL Quotes by TradingView

Jan Skvarka is Director of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 149,551 shares of ZNTL, which is worth approximately $346,958. The most recent transaction as insider was on Jan 31, 2025, when has been sold 60,000 shares (Common Stock) at a price of $1.72 per share, resulting in proceeds of $103,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 150K
67.0% 3M change
211.76% 12M change
Total Value Held $346,958

Jan Skvarka Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 31 2025
BUY
Open market or private purchase
$103,200 $1.72 p/Share
60,000 Added 28.63%
149,551 Common Stock
Jun 21 2024
BUY
Grant, award, or other acquisition
-
41,581 Added 31.71%
89,551 Common Stock
Sep 11 2023
SELL
Open market or private sale
$125,250 $25.05 p/Share
5,000 Reduced 9.44%
47,970 Common Stock
Jun 16 2023
BUY
Grant, award, or other acquisition
-
16,364 Added 23.6%
52,970 Common Stock
Sep 09 2022
BUY
Grant, award, or other acquisition
-
36,606 Added 50.0%
36,606 Common Stock

Also insider at

GLUE
Monte Rosa Therapeutics, Inc. Healthcare
JS

Jan Skvarka

Director
New York, NY

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ZNTL